Ind-Swift Laboratories Share Price

Pharmaceuticals company Ind-Swift Laboratories announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations for Q4FY26 was Rs 16,978.68 lakh, showing a growth of 9.86% QoQ from Rs 15,454.37 lakh in Q3FY26 and 19.26% YoY from Rs 14,236.59 lakh in Q4FY25. Total Income for Q4FY26 stood at Rs 17,200.85 lakh, compared to Rs 17,843.21 lakh in Q3FY26 and Rs 14,205.38 lakh in Q4FY25. Consolidated Net Profit for Q4FY26 was Rs 1,511.21 lakh, reflecting a QoQ increase of 58.44% from Rs 953.83 lakh. YoY performance was lower compared to Rs 22,226.88 lakh in Q4FY25 due to high base exceptional gains in the previous year. For the full year ended FY26, consolidated Revenue from Operations was Rs 64,129.31 lakh, up 11.68% YoY from Rs 57,423.92 lakh in FY25. Consolidated Net Profit for FY26 was Rs 4,141.53 lakh compared to Rs 25,047.65 lakh in FY25. Consolidated Basic EPS for Q4FY26 was Rs 1.81, compared to Rs 1.17 in Q3FY26 and Rs 33.04 in Q4FY25. Standalone Financial Highlights: Revenue from Operations for Q4FY26 stood at Rs 17,270.06 lakh, representing a growth of 12.75% QoQ from Rs 15,317.14 lakh in Q3FY26 and a growth of 15.50% YoY from Rs 14,951.76 lakh in Q4FY25. Total Income for Q4FY26 was Rs 17,491.11 lakh, compared to Rs 17,705.98 lakh in Q3FY26 and Rs 14,915.91 lakh in Q4FY25. Net Profit for Q4FY26 was Rs 1,493.86 lakh, showing a QoQ increase of 39.07% compared to Rs 1,074.18 lakh in Q3FY26. On a YoY basis, it decreased from Rs 21,808.84 lakh in Q4FY25, which was significantly elevated due to a one-time exceptional income gain of Rs 21,587.96 lakh. For the full year ended FY26, standalone Revenue from Operations reached Rs 63,588.85 lakh, an increase of 13.11% over Rs 56,217.34 lakh in FY25. Standalone Net Profit for FY26 stood at Rs 4,255.68 lakh compared to Rs 25,608.52 lakh in FY25. Standalone Basic Earnings Per Share (EPS) for Q4FY26 was Rs 1.79, compared to Rs 1.32 in Q3FY26 and Rs 32.42 in Q4FY25. Business Highlights: Amalgamation: The company completed the amalgamation of Ind Swift Limited (ISL) with itself during the year. The merger became effective on August 8, 2025, and the results for FY26 represent the combined entity. Segment Performance: The company is exclusively engaged in the Pharmaceutical Business segment. Warrant Conversion: During the year, the company converted 1,95,00,000 warrants into an equivalent number of equity shares. A total of 65,00,000 warrants lapsed due to non-exercise of conversion rights by the allottees, and the upfront amount received was forfeited. Exceptional Items: The company recorded exceptional items (income) of Rs 515.24 lakh for Q4FY26 and Rs 1,100.64 lakh for the full year FY26, primarily related to balances written back or written off on account of amounts no longer payable/receivable. Asset Disposal: The company has entered into an agreement to sell the land and building of its Unit-IV located at Baddi. As of March 31, 2026, the company has received Rs 1,710 lakh as part of the sale consideration. Labour Codes: The company has assessed the impact of the new Labour Codes effective November 21, 2025. Based on actuarial valuation, the estimated impact has been recognized and is not material to the results for the year. Investments: As of March 31, 2026, the company held investments in 800 Non-Convertible Debentures (NCD) of M/s. Ashok Investors Trust Ltd, of which 70 debentures have been redeemed. Result PDF

• Trendlyne
• 2 days 13 hours ago

Pharmaceuticals company Ind-Swift Laboratories announced Q3FY26 results Total Revenue: Rs 177.06 crore against Rs 168.3 crore during Q2FY26, change 5%. EBITDA: Rs 9.11 crore against Rs 8.55 crore during Q2FY26, change 7%. EBITDA Margin: 5.95% for Q3FY26. PBT: Rs 17.61 crore against Rs 11.06 crore during Q2FY26, change 59%. PAT: Rs 10.74 crore against Rs 8.76 crore during Q2FY26, change 23%. PAT Margin: 6.07% for Q3FY26. N.R. Munjal Chairman & Whole Time Director, said: “Revenue remained stable for Q3FY26, while a reduction in raw material and employee benefit expenses drove a 6.60% increase in Operating EBITDA and an Operating EBITDA margin expansion of approximately 48 BPS. This improvement in operational efficiency, translated to a 22.60% rise in Net Profit (PAT) QoQ. Ind-Swift Laboratories Ltd has successfully completed a historic strategic reset through the Rs 1,650 crore divestment of its API & CRAMS business. This decisive action, combined with the merger of Ind-Swift Limited into ISLL, has transformed the company into a Net Debt Free entity with a unified operational structure. Currently, we operate as a Pure-Play Formulations Platform with a solid Revenue base of Rs 550 crore, driven primarily by high-quality exports. The restructuring has consolidated our capabilities across manufacturing, R&D; and distribution, positioning the entire organization for scalable, capitalefficient growth. Further we are accelerating execution across high-growth engines by strengthening CDMO visibility through the FY27 accretive Viatris partnership and expanding our Own-Brand footprint in UAE and Central Asia with 400+ registered products. Supported by high-margin segments like Ethical (76% GM), Own-Brand (51% GM) and CMO (42% GM) we are targeting sustained expansion to Double Revenue by FY29 while delivering consistent profitability.” Result PDF

• Trendlyne
• 3 months 3 weeks ago